AP301 peptide clinical trials
Also written AP301.
How each study uses AP301 peptide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the AP301 peptide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2012 (1)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2013 | 1 |
| 2018 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Apeptico Forschung und Entwicklung GmbH (3) · Alebund Pharmaceuticals (2) · Alebund Pty Ltd (1)
Studies
Open first, then newest update. How each study uses AP301 peptide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and ChinaRecruitingPhase 3Alebund PharmaceuticalsNCT06933472Written as AP301
- AP301 Efficacy and Safety in Chinese Dialysis Patients With HyperphosphatemiaCompletedPhase 3Alebund PharmaceuticalsNCT07030595Written as AP301
- Safety and Preliminary Efficacy of Sequential Multiple Ascending Doses of Solnatide to Treat Pulmonary Permeability Oedema in Patients With Moderate-to-severe ARDSCompletedPhase 2Apeptico Forschung und Entwicklung GmbHNCT03567577Written as Solnatide 25 mg powder for reconstitution for solution for inhalation
- A Pharmacodynamic Effect Study of AP301 in Healthy VolunteersCompletedPhase 1Alebund Pty LtdNCT06100627Written as AP301
- Study in Intensive Care Patients Regarding the Effect of Inhaled AP-301 After Primary Graft Dysfunction After Lung TransplantationCompletedPhase 2Apeptico Forschung und Entwicklung GmbHNCT02095626Written as AP-301
- Study in Intensive Care Patients to Investigate the Clinical Effect of Repetitive Orally Inhaled Doses of AP301 on Alveolar Liquid Clearance in Acute Lung InjuryCompletedPhase 2Apeptico Forschung und Entwicklung GmbHNCT01627613Written as AP301
Codes
What other systems call AP301 peptide · ClinicalTrials.gg INT006355
- MeSH (NLM) C583752AP301 peptideOne source NLM
- UNII (FDA) 17ZS80333GSOLNATIDEConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C583752 | AP301 peptide | One source NLM |
| UNII (FDA) | 17ZS80333G | SOLNATIDE | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.